By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The rapid advancements in medical technology have given rise to innovative solutions that promise to transform diabetes management.
Among these breakthroughs, the implantable continuous glucose monitoring (iCGM) system stands out as a revolutionary tool that offers continuous and accurate glucose monitoring without the need for frequent manual testing.
The iCGM system consists of a miniature sensor that is implanted under the skin, usually in the abdominal area.
This sensor continuously measures glucose levels in the interstitial fluid, providing real-time data on the patient’s blood glucose levels throughout the day and night.
The measurements are then wirelessly transmitted to a handheld device or a smartphone app, allowing patients and healthcare providers to access and analyze the data conveniently.
The introduction of the iCGM system addresses several key challenges associated with conventional glucose monitoring methods.
Firstly, it eliminates the pain and discomfort caused by frequent finger stick tests, significantly improving the quality of life for individuals with diabetes.
Secondly, the continuous glucose data enables a comprehensive understanding of glucose fluctuations, enabling better diabetes management decisions.
This includes adjusting insulin doses, dietary choices, and lifestyle modifications, all personalized to the individual’s specific needs.
Moreover, the iCGM system empowers healthcare providers to monitor patients’ glucose levels remotely, allowing for timely interventions, personalized feedback, and adjustments to treatment plans.
This proactive approach can help prevent acute complications, such as hypoglycemia and hyperglycemia, reducing the likelihood of emergency hospital visits and improving overall diabetes outcomes.
The iCGM system’s accuracy and reliability have undergone rigorous testing and received approvals from regulatory bodies, assuring patients and healthcare professionals of its safety and effectiveness.
With continuous advancements in sensor technology and data analytics, the iCGM system is expected to become even more precise and user-friendly in the future.
The Global Implantable continuous glucose monitoring system market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Dexcom G6 is a revolutionary continuous glucose monitoring (CGM) system developed by Dexcom Inc.
It is designed to help individuals with diabetes easily track their glucose levels throughout the day, eliminating the need for frequent finger stick tests.
The G6 sensor is small and discreet, continuously measuring glucose levels just beneath the skin.
Data is wirelessly transmitted to a receiver or compatible smart device, providing real-time glucose readings and trend data.
The system also alerts users to high or low glucose levels, enhancing diabetes management and promoting better decision-making.
Dexcom G6 empowers users to take control of their health and improve their overall quality of life.
The FreeStyle Libre 2 is a product developed by Abbott Diabetes Care Inc, a leading healthcare company.
It is a continuous glucose monitoring system designed for people with diabetes.
The device features a small sensor worn on the back of the upper arm, which continuously measures glucose levels in the interstitial fluid.
Users can scan the sensor with a compatible reader or smartphone to obtain real-time glucose readings, trends, and alerts for high and low glucose levels.
The FreeStyle Libre 2 aims to provide a convenient and effective way for diabetes patients to manage their condition and make informed decisions about their health.
